Day: July 2, 2024

The completion of this assessment verifies SmartGateway’s ability to enhance the overall airport security system TORONTO, July 02, 2024 (GLOBE NEWSWIRE) — Xtract One Technologies (TSX: XTRA)(OTCQX: XTRAF)(FRA: 0PL) (“Xtract One” or the “Company”), a leading technology-driven threat detection and security solution that prioritizes the patron access experience by leveraging AI, today announced that its SmartGateway system has completed an operational test and evaluation by National Safe Skies Alliance, Inc. (“Safe Skies”) at Oakland International Airport. Safe Skies, an independent third-party, non-profit organization funded by the Federal Aviation Administration, conducts thorough testing of security systems’ detection capabilities, reliability, and maintainability under active airport operational and environmental conditions. Safe...

MONTREAL, July 02, 2024 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce high-grade silver drill results from its at-depth drill exploration program at the Zgounder Silver Mine in the Kingdom of Morocco. Highlights (all intersections are in core lengths)In the Central Zone from the 1,950m level:hole DZG-SF-24-065 intercepted 2,870 grams per tonne (“g/t”) silver (“Ag”) over 6.5 meters (“m”), including 7,229 g/t Ag over 2.0m hole DZG-SF-24-057 intercepted 1,252 g/t Ag over 4.0m hole DZG-SF-24-070 intercepted 896 g/t Ag over 6.0m, including 3,820 g/t Ag over 1.0mIn the Western Zone from the 2,000m level:hole DZG-SF-24-027 intercepted 7,631 g/t Ag over 1.5m hole DZG-SF-24-056 intercepted 625 g/t Ag over 14.0m, including 2,677 g/t Ag over 2.0m hole...

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP. ANI’s Naproxen Delayed-Release Tablets is the generic version of the reference listed drug (RLD) EC-Naprosyn®. “We are pleased to announce the first cycle FDA approval and commercialization of Naproxen Delayed-Release Tablets. ANI remains committed to driving growth through superior new product launch execution, in keeping with our purpose of ‘Serving Patients, Improving Lives,’” stated Nikhil Lalwani, President and Chief Executive Officer of ANI. U.S. annual sales for Naproxen Delayed-Release Tablets total approximately $36.7 million,...

CHICAGO, July 02, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 7, 2024. A conference call and webcast with analysts and investors is scheduled for August 7, 2024 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results and answer investor and participant questions.Investors and participants can register in advance for the call by visiting: https://registrations.events/direct/Q4I439151324 After registering, instructions will be shared on how to join the call for those who wish to dial in. On August 7, 2024, the live webcast can be accessed via the following link: https://events.q4inc.com/attendee/694539185 The...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $130.0 million to the Company, before deducting placement agent fees and other offering expenses. The PIPE financing is expected to close on or about July 3, 2024, subject to satisfaction of customary closing conditions. The PIPE financing included participation from both new and existing investors, including HBM Healthcare Investments (Cayman) Ltd., Invus, Schooner Capital, Surveyor Capital (a Citadel company), Timothy A. Springer,...

Trial to assess outpatient administration without lymphodepleting chemotherapy in patients with SLE GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the first patient has been dosed in its Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus (SLE). Descartes-08, Cartesian’s lead mRNA cell therapy candidate and a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T), is an autologous mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). In contrast to conventional DNA-based CAR-T cell therapies, mRNA CAR-T administration is designed not to require...

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced positive topline results from its Phase 2b trial of Descartes-08 in patients with generalized...

2 JULY 2024 RICHEMONT APPOINTS CATHERINE RÉNIER AS CHIEF EXECUTIVE OFFICER OF VAN CLEEF & ARPELS Richemont today announced that Catherine Rénier, currently Chief Executive Officer (CEO) of Jaeger-LeCoultre, will succeed Nicolas Bos as Chief Executive Officer of Van Cleef & Arpels, effective 1 September 2024, and will report to him following his recent appointment as Richemont’s CEO. Mrs Rénier, a French national, brings more than 20 years of jewellery and luxury watchmaking experience at Richemont. She joined the Group in 1999 as Cartier North America’s Retail Development Director in New York. In 2003 she moved to Paris to join Van Cleef & Arpels as Deputy Marketing Manager, where she contributed to the development of the Maison. In 2008, she relocated to Hong Kong to support the Maison’s growth in the Asia Pacific Region,...

SHANGHAI, July 02, 2024 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World” or the “Company”), a key player in the global hotel industry, today announced that (i) Mr. Shangzhi Zhang will step down as a director of the board of directors of the Company (the “Board”) and serve as an observer of the Board, effective from July 2, 2024, and (ii) Ms. Jie Zheng, a senior advisor of the Company and a supervisory board member of Steigenberger Hotels GmbH, a subsidiary of the Company, will serve as an executive director of the Board, effective from the same date. Ms. Zheng has over 20 years of leadership experience across automotive and hospitality sectors both in China and internationally. Ms. Zheng is currently a venture partner of Peeli Ventures, where she provides management consulting for portfolio companies...

GOLDEN, Colo., July 02, 2024 (GLOBE NEWSWIRE) — Truleum, Inc. (Pink OTC Markets: TRLM), is pleased to provide an important update to its shareholders regarding recent developments concerning the Company’s auditor and the status of its S-1 registration statement. On May 3, 2024, BF Borgers CPA PC (“Borgers”), the Company’s former auditor, was the subject of an SEC Enforcement action. The action resulted in Borgers being prohibited from practicing as an accountant/auditor before the SEC. It is important to note that this enforcement action does not affect the Company’s prior public filings, where Borgers provided audits and opinions. However, this development has impacted the Company’s first quarter 2024 financials and its pending S-1 registration statement. In response to these events, Truleum,...